睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由厦门大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07749365,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).

    入选标准第 3 条

  3. Symptomatic congestive heart failure (NYHA class II-IV), symptomatic or poorly controlled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) >500 ms (Fridericia correction).

    排除标准第 12 条

  4. All participants with reproductive potential (male or female) must use highly effective contraception with a failure rate <1% per year during treatment and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

    入选标准第 13 条

  5. Total bilirubin ≤1.5 × upper limit of normal (ULN);

    入选标准第 8 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN;

    入选标准第 9 条

    Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min (calculated using the Cockcroft-Gault formula);

    入选标准第 10 条

    Inadequate bone marrow reserve, defined as platelet count <30 ×10⁹/L or absolute neutrophil count <1.0 ×10⁹/L.

    排除标准第 7 条

  6. B-cell non-Hodgkin lymphoma with at least one measurable lesion according to RECIST 1.1 criteria, or detectable abnormal monoclonal B cells by cerebrospinal fluid (CSF) flow cytometry.

    入选标准第 6 条

  7. HBV DNA >2,000 IU/mL or >10⁴ copies/mL without willingness to receive regular antiviral therapy;

    排除标准第 3 条

    HCV RNA >10³ copies/mL;

    排除标准第 4 条

    Concurrent positivity for HBsAg and anti-HCV antibody.

    排除标准第 5 条

    Receipt of anti-hematologic malignancy therapy within 2 weeks or within 5 pharmacokinetic half-lives before treatment initiation, whichever is longer.

    排除标准第 6 条

    Receipt of hypofractionated radiotherapy within 4 weeks before the first treatment. Patients receiving radiotherapy >4 weeks before enrollment must have no ongoing radiation-related toxicities, no requirement for corticosteroids, and no evidence of radiation pneumonitis, hepatitis, enteritis, or other radiation-related complications.

    排除标准第 13 条

    HIV infection (positive HIV-1/2 antibody) or known syphilis infection.

    排除标准第 16 条

  8. Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study treatment (Cycle 1 Day 1). If urine pregnancy testing cannot confirm a negative result, a serum pregnancy test is required. Women of non-childbearing potential are defined as those who are postmenopausal for ≥1 year or have undergone surgical sterilization or hysterectomy.

    入选标准第 12 条

    Pregnant or breastfeeding women.

    排除标准第 23 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07749365,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Written informed consent must be obtained before any study-related procedures.
  2. Age ≥18 years, regardless of sex, with an expected survival time >3 months.
  3. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
  4. Newly diagnosed patients with primary central nervous system diffuse large B-cell lymphoma (PCNSL).
  5. No previous treatment with bispecific antibodies.
  6. B-cell non-Hodgkin lymphoma with at least one measurable lesion according to RECIST 1.1 criteria, or detectable abnormal monoclonal B cells by cerebrospinal fluid (CSF) flow cytometry.
  7. Adequate organ function meeting the following laboratory criteria:
  8. Total bilirubin ≤1.5 × upper limit of normal (ULN);
  9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN;
  10. Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min (calculated using the Cockcroft-Gault formula);
  11. Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN.
  12. Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study treatment (Cycle 1 Day 1). If urine pregnancy testing cannot confirm a negative result, a serum pregnancy test is required. Women of non-childbearing potential are defined as those who are postmenopausal for ≥1 year or have undergone surgical sterilization or hysterectomy.
  13. All participants with reproductive potential (male or female) must use highly effective contraception with a failure rate <1% per year during treatment and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

排除标准:Exclusion Criteria:

  1. Loss of CD20 expression in B-cell non-Hodgkin lymphoma.
  2. Active acute or chronic hepatitis B or hepatitis C infection, including:
  3. HBV DNA >2,000 IU/mL or >10⁴ copies/mL without willingness to receive regular antiviral therapy;
  4. HCV RNA >10³ copies/mL;
  5. Concurrent positivity for HBsAg and anti-HCV antibody.
  6. Receipt of anti-hematologic malignancy therapy within 2 weeks or within 5 pharmacokinetic half-lives before treatment initiation, whichever is longer.
  7. Inadequate bone marrow reserve, defined as platelet count <30 ×10⁹/L or absolute neutrophil count <1.0 ×10⁹/L.
  8. Clinically significant pulmonary diseases, including:
  9. Chronic obstructive pulmonary disease (COPD) with FEV1 <50% of predicted value;
  10. Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any severity.
  11. Uncontrolled hypertension despite optimal medical management (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg), history of hypertensive crisis, or hypertensive encephalopathy.
  12. Symptomatic congestive heart failure (NYHA class II-IV), symptomatic or poorly controlled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) >500 ms (Fridericia correction).
  13. Receipt of hypofractionated radiotherapy within 4 weeks before the first treatment. Patients receiving radiotherapy >4 weeks before enrollment must have no ongoing radiation-related toxicities, no requirement for corticosteroids, and no evidence of radiation pneumonitis, hepatitis, enteritis, or other radiation-related complications.
  14. Difficulty swallowing oral medications.
  15. History or presence of pulmonary fibrosis, interstitial lung disease, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction.
  16. HIV infection (positive HIV-1/2 antibody) or known syphilis infection.
  17. Presence of unhealed wounds, fractures, gastric or duodenal ulcers, persistent positive fecal occult blood test, ulcerative colitis, or other conditions associated with risk of gastrointestinal bleeding or perforation as determined by the investigator.
  18. Active or uncontrolled severe infection, including severe infection requiring hospitalization due to infection, bacteremia, or severe pneumonia within 4 weeks before the first dose.
  19. Major surgery or significant traumatic injury within 4 weeks before the first dose.
  20. Use of traditional Chinese medicine with antitumor indications within 2 weeks before the first dose.
  21. Known hypersensitivity to any component of bispecific antibodies or GM-CSF preparations.
  22. Receipt of treatment in another clinical trial within 4 weeks before the first dose.
  23. Pregnant or breastfeeding women.
  24. Active autoimmune disease or history of autoimmune disease, including but not limited to autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, and nephritis. Patients requiring medical intervention with bronchodilators for asthma are excluded. The following conditions are permitted: vitiligo, psoriasis, alopecia, or controlled type I diabetes not requiring systemic treatment, and hypothyroidism controlled with hormone replacement therapy.
  25. Any other acute or chronic disease, psychiatric condition, or abnormal laboratory finding that may:
  26. Increase the risk associated with study participation or administration of study treatment;
  27. Interfere with interpretation of study results;
  28. Render the patient unsuitable for participation according to the investigator's judgment.

引自 ClinicalTrials.gov, NCT07749365, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07749365,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07749365